Non-valvular atrial fibrillation in the elderly; preliminary results from the National AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) Study

Basit Öğe Kaydı
dc.contributor.authorErtas, F.
dc.contributor.authorOylumlu, M.
dc.contributor.authorAkil, M. A.
dc.contributor.authorAcet, H.
dc.contributor.authorBilik, M. Z.
dc.contributor.authorCelepkolu, T.
dc.contributor.authorYildiz, A.
dc.date.accessioned2024-04-24T17:37:41Z
dc.date.available2024-04-24T17:37:41Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractOBJECTIVE: This study aimed at the assessment of the clinical approach to atrial fibrillation (AF) in the older population and the consistency with the guidelines based on the records of the multicenter, prospective AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) study. PATIENTS AND METHODS: 2242 consecutive patients admitted to the Cardiology Outpatient Clinics of 17 different tertiary Health Care Centers with at least one AF attack determined on electrocardiographic examination, were included in the study. Among the patients included in the study, 631 individuals aged 75 years and older were analyzed. RESULTS: The mean age of the patients was determined as 80.3 +/- 4.2 years. The most frequent type of AF in geriatric population was the persistent-permanent type with a percentage of 88%. 60% of the patients with AF were female. Hypertension was the most common co-morbidity in patients with AF (76%). While in 16% of patients a history of stroke, transient ischemic attack or systemic thromboembolism was present, a history of bleeding was present in 14% of the patients. 37% of the patients were on warfarin treatment and 60% of the patients were on aspirin treatment. In 38% of the patients who were on oral anticoagulant treatment, INR level was in the effective range. CONCLUSIONS: The rate of anticoagulant use in the elderly with AF was 37% and considering the reason of this situation was the medication not being prescribed by the physician, one should pay more attention particularly in the field of treatment.en_US
dc.identifier.endpage1016en_US
dc.identifier.issn1128-3602
dc.identifier.issue8en_US
dc.identifier.pmid23661513
dc.identifier.scopus2-s2.0-84878581793
dc.identifier.scopusqualityQ2
dc.identifier.startpage1012en_US
dc.identifier.urihttps://hdl.handle.net/11468/21126
dc.identifier.volume17en_US
dc.identifier.wosWOS:000319517900003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectAnticoagulationen_US
dc.subjectElderlyen_US
dc.subjectPredictoren_US
dc.titleNon-valvular atrial fibrillation in the elderly; preliminary results from the National AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) Studyen_US
dc.titleNon-valvular atrial fibrillation in the elderly; preliminary results from the National AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu